RecruitingNCT06663696

CRUZ Tunisia-Multivessel Registry

Evaluation of the Safety and Clinical Performance of the Biodegradable Polymer-Coated Sirolimus-Eluting Stent in All-Comer Patients With Multivessel Coronary Artery Disease

Sponsor

Sahajanand Medical Technologies Limited

Enrollment

1,000 participants

Start Date

Nov 1, 2024

Study Type

OBSERVATIONAL

Conditions

Patient Population With Multivessel Disease

Summary

The primary objective of this registry is to evaluate the safety and clinical performance of the biodegradable polymer-coated Supraflex Cruz Sirolimus-eluting Stent (SES) in an unselected, all-comer patient population with multivessel disease. This population represents daily clinical practice and includes patients requiring coronary revascularization with drug-eluting stents (DES).

Eligibility

Min Age: 18 YearsMax Age: 99 Years

Plain Language Summary

Simplified for easier understanding

This clinical trial is studying a medical device called Supraflex Cruz Sirolimus-eluting Coronary Stent System for people with patient population with multivessel disease. The study is currently recruiting participants at 2 locations. People eligible for this study include aged 18 Years to 99 Years.

This summary was AI-generated to explain the trial in plain language. It is not medical advice. Always discuss eligibility with your doctor before enrolling in a clinical trial.

Interested in this trial?

Get notified about updates and connect with the research team.

Interventions

DEVICESupraflex Cruz Sirolimus-eluting Coronary Stent System

Biodegradable polymer-coated, cobalt-chromium sirolimus-eluting coronary stent

Locations(2)

Sahloul Hospital

Sousse, Tunisia

Habib Thameur Hospital

Tunis, Tunisia

View Full Details on ClinicalTrials.gov

For the most up-to-date information, visit the official listing.

Visit

NCT06663696